LIVZON PHARMAC. GRP H YC1 (F:LP6) — Stock Price
LIVZON PHARMAC. GRP H YC1 (F:LP6) is currently trading at €2.42 EUR, up 5.22% today. Over the past 52 weeks, shares have ranged between €2.08 and €3.80. This page tracks LIVZON PHARMAC. GRP H YC1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see cash efficiency ratio of LIVZON PHARMAC. GRP H YC1.
LIVZON PHARMAC. GRP H YC1 (LP6) Stock Price Chart — Daily History & Trading Volume
The chart below tracks LIVZON PHARMAC. GRP H YC1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
LIVZON PHARMAC. GRP H YC1 Income Statement — Revenue, Profit & Earnings by Year
LIVZON PHARMAC. GRP H YC1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €12.02 Billion | €11.81 Billion | €12.43 Billion | €12.63 Billion | €12.06 Billion |
| Cost of Revenue | €4.10 Billion | €4.08 Billion | €4.47 Billion | €4.46 Billion | €4.25 Billion |
| Gross Profit | €7.92 Billion | €7.73 Billion | €7.96 Billion | €8.17 Billion | €7.81 Billion |
| Research & Development | €937.95 Million | €1.03 Billion | €1.33 Billion | €1.43 Billion | €1.15 Billion |
| SG&A | €3.30 Billion | €2.97 Billion | €3.51 Billion | €3.76 Billion | €3.85 Billion |
| Total Operating Expenses | €9.25 Billion | €8.98 Billion | €10.00 Billion | €10.40 Billion | €9.88 Billion |
| Operating Income | €2.77 Billion | €2.83 Billion | €2.43 Billion | €2.23 Billion | €2.19 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €57.21 Million | €88.61 Million | €102.09 Million | €97.55 Million | €84.00 Million |
| Income Before Tax | €2.86 Billion | €2.81 Billion | €2.38 Billion | €2.33 Billion | €2.25 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €2.02 Billion | €2.06 Billion | €1.95 Billion | €1.91 Billion | €1.78 Billion |
LIVZON PHARMAC. GRP H YC1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes LIVZON PHARMAC. GRP H YC1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €23.99 Billion | €24.46 Billion | €25.04 Billion | €24.87 Billion | €22.37 Billion |
| Total Current Assets | €16.12 Billion | €16.42 Billion | €17.27 Billion | €16.99 Billion | €14.67 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €1.34 Billion | €89.36 Million | €81.79 Million | €108.09 Million | €182.77 Million |
| Net Receivables | €2.25 Billion | €1.94 Billion | €2.12 Billion | €2.42 Billion | €1.95 Billion |
| Inventory | €1.56 Billion | €2.00 Billion | €2.06 Billion | €2.05 Billion | €1.66 Billion |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €124.91 Million | €124.91 Million | €124.91 Million | €103.04 Million | €103.04 Million |
| Total Liabilities | €8.44 Billion | €9.55 Billion | €10.28 Billion | €9.93 Billion | €8.06 Billion |
| Total Current Liabilities | €7.22 Billion | €7.63 Billion | €8.09 Billion | €7.40 Billion | €6.93 Billion |
| Long-term Debt | €749.36 Million | €1.47 Billion | €1.61 Billion | €1.97 Billion | €636.78 Million |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €13.89 Billion | €13.86 Billion | €14.04 Billion | €13.88 Billion | €13.00 Billion |
| Retained Earnings | €12.74 Billion | €11.76 Billion | €10.91 Billion | €10.44 Billion | €9.72 Billion |
LIVZON PHARMAC. GRP H YC1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how LIVZON PHARMAC. GRP H YC1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €3.15 Billion | €2.98 Billion | €3.25 Billion | €2.77 Billion | €1.90 Billion |
| Capital Expenditures | €574.14 Million | €570.16 Million | €820.45 Million | €940.15 Million | €1.31 Billion |
| Free Cash Flow | €2.57 Billion | €2.41 Billion | €2.43 Billion | €1.83 Billion | €593.23 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | €1.03 Billion | €1.34 Billion | €1.59 Billion | €1.30 Billion | €1.26 Billion |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | €574.03 Million | €575.14 Million | €840.32 Million | €652.32 Million | €445.27 Million |
| Change in Cash | €-3.38 Billion | €-158.55 Million | €903.72 Million | €947.33 Million | €-826.74 Million |
LIVZON PHARMAC. GRP H YC1 Earnings History — EPS Actual vs. Analyst Estimates
Track LIVZON PHARMAC. GRP H YC1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jul 23, 2026 | — | 0.64 | — |
| Apr 23, 2026 | — | 0.72 | — |
| Mar 26, 2026 | — | 0.37 | — |
| Oct 21, 2025 | — | — | — |
| Apr 21, 2025 | — | — | — |